The GABAA receptor alpha+beta- interface: a novel target for subtype selective drugs.
GABA(A) receptors mediate the action of many clinically important drugs interacting with different binding sites. For some potential binding sites, no interacting drugs have yet been identified. Here, we established a steric hindrance procedure for the identification of drugs acting at the extracellular α1+β3- interface, which is homologous to the benzodiazepine binding site at the α1+γ2- interface. On screening of >100 benzodiazepine site ligands, the anxiolytic pyrazoloquinoline 2-p-methoxyphenylpyrazolo[4,3-c]quinolin-3(5H)-one (CGS 9895) was able to enhance GABA-induced currents at α1β3 receptors from rat. CGS 9895 acts as an antagonist at the benzodiazepine binding site at nanomolar concentrations, but enhances GABA-induced currents via a different site present at α1β3γ2 and α1β3 receptors. By mutating pocket-forming amino acid residues at the α1+ and the β3- side to cysteines, we demonstrated that covalent labeling of these cysteines by the methanethiosulfonate ethylamine reagent MTSEA-biotin was able to inhibit the effect of CGS 9895. The inhibition was not caused by a general inactivation of GABA(A) receptors, because the GABA-enhancing effect of ROD 188 or the steroid α-tetrahydrodeoxycorticosterone was not influenced by MTSEA-biotin. Other experiments indicated that the CGS 9895 effect was dependent on the α and β subunit types forming the interface. CGS 9895 thus represents the first prototype of drugs mediating benzodiazepine-like modulatory effects via the α+β- interface of GABA(A) receptors. Since such binding sites are present at αβ, αβγ, and αβδ receptors, such drugs will have a much broader action than benzodiazepines and might become clinical important for the treatment of epilepsy.
Department of Biochemistry and Molecular Biology, Center for Brain Research, Medical University Vienna, Austria.
Joachim
J
Ramerstorfer
Roman
R
Furtmüller
Isabella
I
Sarto-Jackson
Zdravko
Z
Varagic
Werner
W
Sieghart
Margot
M
Ernst
D000704:Analysis of Variance; D000818:Animals; D001665:Binding Sites / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004594:Electrophysiology; D005442:Flumazenil / Q000494:pharmacology; D058785:GABA-A Receptor Agonists / Q000494:pharmacology*; D021122:Protein Subunits / Q000502:physiology*; D011720:Pyrazoles / Q000494:pharmacology; D011963:Receptors, GABA-A / Q000502:physiology*; D014982:Xenopus laevis; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology
D058785:GABA-A Receptor Agonists; D021122:Protein Subunits; D011720:Pyrazoles; D011963:Receptors, GABA-A; D005442:Flumazenil; D005680:gamma-Aminobutyric Acid; C039232:2,5-dihydro-2-(4-methoxyphenyl)-3H-pyrazolo(4,3-c)quinolin-3-one
J Biol Chem. 2007 Sep 7;282(36):26316-25
17626010
J Neurosci. 1997 Apr 15;17(8):2728-37
9092594
Nat Neurosci. 2000 Dec;3(12):1274-81
11100148
J Med Chem. 1982 Apr;25(4):337-9
6121916
J Biol Chem. 1999 Apr 9;274(15):10100-4
10187791
Trends Pharmacol Sci. 1995 May;16(5):162-8
7624971
Eur J Neurosci. 1997 Nov;9(11):2225-35
9464918
Mol Pharmacol. 2005 Nov;68(5):1291-300
16103045
Eur J Pharmacol. 2010 Jun 25;636(1-3):18-27
20303942
J Biol Chem. 2001 Sep 28;276(39):36275-80
11466317
Pharmacol Rev. 2008 Sep;60(3):243-60
18790874
J Neurosci. 2001 Jul 15;21(14):4977-86
11438573
Proc Natl Acad Sci U S A. 2006 May 30;103(22):8546-51
16581914
Neuropharmacology. 1996;35(9-10):1323-30
9014148
Methods Enzymol. 1993;217:270-9
8474334
Mol Pharmacol. 1995 Dec;48(6):965-9
8848011
Eur J Pharmacol. 1984 Aug 3;103(1-2):139-43
6090169
Br J Pharmacol. 2000 Oct;131(4):843-50
11030736
J Biol Chem. 1997 May 2;272(18):11723-7
9115225
Curr Top Med Chem. 2002 Aug;2(8):833-9
12171574
J Neurochem. 2008 Sep;106(6):2353-63
18643789
Neuron. 1990 Nov;5(5):703-11
1699569
Physiol Behav. 1987;41(3):241-5
2893398
Pharmacol Rev. 1995 Jun;47(2):181-234
7568326
Eur J Pharmacol. 1984 Oct 30;106(1):167-73
6099267
Mol Pharmacol. 1995 Sep;48(3):385-91
7565617
J Med Chem. 2003 Dec 18;46(26):5567-70
14667209
Nat Rev Neurosci. 2005 Mar;6(3):215-29
15738957
Neuroscience. 2003;119(4):933-43
12831854